stockrow
Friday 6 November 2026
Export NAMS’s income statement to Excel — free account
NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
19.29
0.40
+2.12%
Follow NAMS
Alert me
NewAmsterdam Pharma Company N.V. (NAMS) Revenue growth
NewAmsterdam Pharma Company N.V.'s revenue growth over the twelve months to 30 September 2026 was −26.4%, up 24.2 percentage points from fiscal 2025 (−50.6%). That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −50.6% | (273.98) |
| FY2024 | 223.4% | 309.65 |
| FY2023 | −86.3% | (86.50) |
| FY2022 | 0.22% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 5,406.9% | 5,487.57 |
| Jun 2026 | −80.7% | (82.75) |
| Mar 2026 | 2.08% | 101.83 |
| Dec 2025 | −99.8% | (0.95) |
| 7 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | 146.7% |
| RXRX Recursion Pharmaceuticals, Inc. compare | 56.2% |
| ADMA ADMA Biologics Inc compare | 6.26% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.02% |
| NAMS NewAmsterdam Pharma Company N.V. | −26.4% |
| XNCR Xencor, Inc. compare | −28.6% |
| CLDX Celldex Therapeutics, Inc. compare | −88.3% |
| PHVS Pharvaris N.V. compare | — |
| MBX MBX Biosciences, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on NAMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement